Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Generation Bio Co (NASDAQ: GBIO) was $2.85 for the day, down -1.72% from the previous closing price of $2.90. In other words, the price has decreased by -$1.72 from its previous closing price. On the day, 0.81 million shares were traded. GBIO stock price reached its highest trading level at $3.05 during the session, while it also had its lowest trading level at $2.85.
Ratios:
Our analysis of GBIO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.83 and its Current Ratio is at 6.83. In the meantime, Its Debt-to-Equity ratio is 0.48 whereas as Long-Term Debt/Eq ratio is at 0.44.
On November 08, 2022, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $9.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 02 ’24 when Samayoa Phillip sold 2,445 shares for $1.62 per share. The transaction valued at 3,961 led to the insider holds 107,256 shares of the business.
Paone Antoinette sold 2,445 shares of GBIO for $3,961 on Jan 02 ’24. The CHIEF OPERATING OFFICER now owns 5,828 shares after completing the transaction at $1.62 per share. On Dec 08 ’23, another insider, Appelhans Dannielle, who serves as the Director of the company, bought 7,363 shares for $1.79 each. As a result, the insider paid 13,180 and bolstered with 7,363 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GBIO now has a Market Capitalization of 192783680 and an Enterprise Value of 22989766. For the stock, the TTM Price-to-Sale (P/S) ratio is 32.12 while its Price-to-Book (P/B) ratio in mrq is 0.93. Its current Enterprise Value per Revenue stands at 3.894 whereas that against EBITDA is -0.172.
Stock Price History:
The Beta on a monthly basis for GBIO is 2.86, which has changed by -0.37908494 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, GBIO has reached a high of $6.98, while it has fallen to a 52-week low of $0.86. The 50-Day Moving Average of the stock is -8.35%, while the 200-Day Moving Average is calculated to be -2.11%.
Shares Statistics:
GBIO traded an average of 239.70K shares per day over the past three months and 238190 shares per day over the past ten days. A total of 66.21M shares are outstanding, with a floating share count of 48.53M. Insiders hold about 27.00% of the company’s shares, while institutions hold 66.99% stake in the company. Shares short for GBIO as of 1713139200 were 1584839 with a Short Ratio of 6.61, compared to 1710460800 on 1269221. Therefore, it implies a Short% of Shares Outstanding of 1584839 and a Short% of Float of 4.0599998.
Earnings Estimates
The company has 7.0 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.41 for the current quarter, with a high estimate of -$0.27 and a low estimate of -$0.57, while EPS last year was -$0.53. The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.24 and low estimates of -$0.52.
Analysts are recommending an EPS of between -$1.06 and -$2.04 for the fiscal current year, implying an average EPS of -$1.49. EPS for the following year is -$1.3, with 7.0 analysts recommending between -$0.52 and -$1.96.
